MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
7.37
+0.37 (5.29%)
At close: Mar 9, 2026, 4:00 PM EDT
7.34
-0.03 (-0.41%)
After-hours: Mar 9, 2026, 7:05 PM EDT
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $410.00K in the quarter ending September 30, 2025, a decrease of -96.24%. This brings the company's revenue in the last twelve months to $27.42M, up 96.83% year-over-year. In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth.
Revenue (ttm)
$27.42M
Revenue Growth
+96.83%
P/S Ratio
21.64
Revenue / Employee
$67,034
Employees
409
Market Cap
593.22M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| Fulcrum Therapeutics | 80.00M |
| Verastem | 30.91M |
| Ocugen | 4.41M |
| YD Bio | 510.36K |
MGTX News
- 4 weeks ago - ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy - PRNewsWire
- 3 months ago - Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference - PRNewsWire
- 4 months ago - MeiraGTx Reports Third Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 4 months ago - Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease - Reuters
- 4 months ago - MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology - GlobeNewsWire
- 5 months ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 7 months ago - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 10 months ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire